0
Boehringer Ingelheim informed today about its performance on the Chinese market in the business year 2012. With sales of 358 Mill Euro/2,904 mio RMB which marks a growth of 32% in 2012, it will accelerate its strategic business development in China, a market of significant importance to the company. With the aim of improving health to better the quality of life for patients across China, Boehringer Ingelheim is focused on driving future and sustained growth across four key strategic areas – prescription medicine, consumer healthcare, animal health, and the future introduction and operation of its biopharmaceutical business. Underpinned by unwavering commitment to innovation and the delivery of high quality healthcare solutions, the company is confident in achieving continued substantial growth in China in 2013 and beyond.
"We see significant potential in China as one of the major strategic markets for the company’s future growth," said Professor Andreas Barner, Chairman of the Board of Managing Directors. "We are committed to investing and to introducing more innovative medicines and animal health solutions in China."
An Established Market Leader in Animal Health
Boehringer Ingelheim’s animal health business ranked No. 3 amongst international companies in 2012 in China. As a market leader, Boehringer Ingelheim China is highly competitive in the area of animal vaccines, with acclaimed market reputation for quality and distribution across all core products, including Ingelvac Circoflex® which helps to protect pigs against Porcine Circovirus Disease.
In March 2012, the 12million euro Boehringer Ingelheim Asian Veterinary Research and Development Center (AVRDC) opened in Zhangjiang, Shanghai to expand innovative vaccine development against swine and poultry diseases; thus, helping to safeguard China’s animal husbandry industry. In addition, in May 2012, Boehringer Ingelheim initiated a joint venture with China Medical City to build a new state-of-the-art vaccine manufacturing facility in Taizhou, Jiangsu Province. With a total investment of more than 55 million euros, the new manufacturing facility, scheduled to break ground in 2013, will produce swine and poultry vaccines for China and other Asian markets.
"Our aim is to maintain and extend our leadership position in China’s animal health business" said Dr. Joachim Hasenmaier. "We will expand our cattle business and introduce our pet animal health business to China. We will further extend our product line in the future, aiming to become the reliable partner of choice for China’s animal breeders and to contribute to food safety in China. With strong scientific discovery and development capabilities, Boehringer Ingelheim is also prepared to enter into possible cooperations to assist the Chinese government in order to accelerate the development of vaccines against the recent H7N9 avian flu detected in poultry in China," he added.
April 25, 2013 - Boehringer
